Cardiovascular and non‐renal complications of chronic kidney disease: Managing risk
Why the study?
Excess mortality in CKD is mostly driven by cardiovascular disease, and implementation of new organ-protective opportunities remains a challenge.
Population
People with CKD
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
May support prioritizing these therapies in HFrEF-CKD overlap; extends syntheses but leaves optimal combinations open.
Structured PICO
P
Population
People with chronic kidney disease (CKD) and associated cardiovascular complications (heart failure, atherosclerotic cardiovascular disease, atrial fibrillation)
I
Intervention
Management of risk factors and organ-protective interventions (renin-angiotensin system blockade, sodium-glucose cotransporter-2 inhibition, mineralocorticoid receptor antagonism)
This review emphasizes the importance of managing cardiovascular risk factors and utilizing organ-protective therapies like SGLT2 inhibitors and MRAs to mitigate cardiovascular and non-renal complications in patients with chronic kidney disease.
Cite This Study
Rossing et al. (2024) studied this question.